Clinical trial
An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
NCT00057239 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00057239 |
|---|---|
| Title | An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder |
| Official title | A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy, Safety and Tolerability of Two Doses (20mg and 60mg) of a Once-Daily Oral Formulation of GW353162 in Subjects With Major Depressive Disorder for a Treatment Period of Eight Weeks |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder (MDD) |
| Intervention type | Drug |
| Interventions | Radafaxine |
| Enrollment | 546 |
| Start date | Mar 1, 2003 |
| Primary completion | May 1, 2004 |
| Completion | May 1, 2004 |
| First posted | Mar 28, 2003 |
| Last update posted | Oct 4, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: